CT-152 could leverage evidence-based cognitive therapy to help a wide range of patients suffering from major depressive disorder.
Otsuka America and Click Therapeutics today announced that the companies agreed to collaborate to develop and commercialize a prescription digital therapeutic for the treatment of major depressive disorder.
Otsuka, a global healthcare company that focuses on developing, manufacturing and marketing innovative products, agreed to fully fund the development of Click’s mobile application, CT-152. The company will pay Click up to $10 million in upfront and regulatory milestone payments and approximately $20 million in development funding. $272 million in commercial milestone payments are also contingent upon approval.
>> READ: Reducing Depression Symptoms with Digital Health Tools
The company hopes to commercialize the application world-wide after being granted regulatory approvals.
“Our goal is to deliver evidence-based cognitive therapies to a broader population of patients with (major depressive disorder) than is currently feasible, due to the challenges of a shortage of mental health professionals and limited time for them to conduct cognitive therapy,” said Kabir Nath, president and CEO of Otsuka North America Pharmaceutical Business Division, Otsuka America.
CT-152 could leverage evidence-based cognitive therapy principles and Click’s patient engagement platform to treat patients independently or in conjunction with prescribed medications.
The software is still being developed, but Nath told Healthcare Analytics News™ that the company has spent the last few years reviewing the landscape of developers and designers to establish the best product.
Depression is the leading cause of disability worldwide, according to the World Health Organization, and Otsuka and Click want to use technology and data to support better patient outcomes.
Click has already established itself in the world of digital therapeutics with its smoking cessation app called Clickotine and is working on other therapeutics for acute coronary syndrome, insomnia and chronic pain.
Nath told Healthcare Analytics News™ that a clinical trial of CT-152 may happen at the close of 2019.
Get the best insights in healthcare analytics directly to your inbox.
Digital Therapeutic Freespira Gets FDA OK to Treat PTSD
After FDA Approval, Pear Therapeutics Releases Drug Treatment mHealth App reSET